Original Research Article

Integrating and validating automated digital imaging analysis of estrogen receptor immunohistochemistry in a fully digital workflow for clinical use

Saba Shafi, David A. Kellough, Giovanni Lujan, Swati Satturwar, Anil V. Parwani, Zaibo Li

Background: The Visiopharm automated estrogen receptor (ER) digital imaging analysis (DIA) algorithm assesses digitized ER immunohistochemistry (IHC) by segmenting tumor nuclei and detecting stained nuclei automatically. We aimed to integrate and validate this algorithm in a digital pathology workflow for clinical use.

Design: The study cohort consisted of a serial collection of 97 invasive breast carcinoma specimens including 73 biopsies and 24 resections. ER IHC slides were scanned into Philips Image Management System (IMS) during our routine digital workflow and digital images were directly streamed into Visiopharm platform and analyzed using automated ER algorithm to obtain the positively stained tumor nuclei and staining intensity. ER DIA scores were compared with pathologists’ manual scores.

Results: The overall concordance between pathologists’ reads and DIA reads was excellent (91/97, 93.8%). Pearson Correlation Coefficient of the percentage of ER positive nuclei between the original reads and VIS reads was 0.72. Six cases (3 ER-negative and 3 ER-positive) had discordant results. All 3 false negative cases had very weak ER staining and no more than 10% positivity. The causes for false positive DIA were mainly pre-analytic/pre-imaging and included intermixed benign glands in tumor area, ductal carcinoma in-situ (DCIS) components, and tissue folding.

Conclusions: Automated ER DIA demonstrates excellent concordance with pathologists’ scores and accurately discriminates ER positive from negative cases. Furthermore, integrating automated biomarker DIA into a busy clinical digital workflow is feasible and may save time and labor for pathologists.

**A B S T R A C T**

**Key words:** ER, Digital image analysis, Visiopharm, Breast cancer, Clinical

**A R T I C L E   I N F O**

**Background:** The Visiopharm automated estrogen receptor (ER) digital imaging analysis (DIA) algorithm assesses digitized ER immunohistochemistry (IHC) by segmenting tumor nuclei and detecting stained nuclei automatically. We aimed to integrate and validate this algorithm in a digital pathology workflow for clinical use.

**Design:** The study cohort consisted of a serial collection of 97 invasive breast carcinoma specimens including 73 biopsies and 24 resections. ER IHC slides were scanned into Philips Image Management System (IMS) during our routine digital workflow and digital images were directly streamed into Visiopharm platform and analyzed using automated ER algorithm to obtain the positively stained tumor nuclei and staining intensity. ER DIA scores were compared with pathologists’ manual scores.

**Results:** The overall concordance between pathologists’ reads and DIA reads was excellent (91/97, 93.8%). Pearson Correlation Coefficient of the percentage of ER positive nuclei between the original reads and VIS reads was 0.72. Six cases (3 ER-negative and 3 ER-positive) had discordant results. All 3 false negative cases had very weak ER staining and no more than 10% positivity. The causes for false positive DIA were mainly pre-analytic/pre-imaging and included intermixed benign glands in tumor area, ductal carcinoma in-situ (DCIS) components, and tissue folding.

**Conclusions:** Automated ER DIA demonstrates excellent concordance with pathologists’ scores and accurately discriminates ER positive from negative cases. Furthermore, integrating automated biomarker DIA into a busy clinical digital workflow is feasible and may save time and labor for pathologists.
Estrogen receptor immunohistochemistry

Estrogen receptor (ER) protein was assessed on formalin-fixed paraffin embedded (FFPE) (ischemic time < 1 h and fixation time between 6 and 72 h) whole tissue sections by immunohistochemistry (IHC). An automated deparaffinization step was followed by cell conditioning and then rinsing and incubation with the pre-diluted anti-ER antibody clone SP1 (Spring Bioscience) at 37 °C. Staining was performed using Leica/Bond polymer detection system on a Leica/Bond auto-stainer. The slides were counterstained, then rinsed and cover slipped. Pathologists’ scoring

ER IHC was manually scored as a percentage of positive tumor cell nuclei and staining intensity according to ASCO/CAP guidelines. The percentage of positive tumor cell nuclei was categorized as <1% (negative), 1–10% (low positive), or >10% (positive). The overall staining intensity was categorized as weak, moderate, or strong. ER IHC results were signed out by board-certified breast pathologists (original reads). In addition, 2 pathologists independently scored ER IHCs by manual semi-quantification during this study.

Image acquisition, management, and automated digital image analysis (DIA)

ER IHC slides were scanned into whole slide images (WSI) using the Philips scanners and stored in Philips Image Management System (IMS) consisting of Philips IntelliSite Pathology Solution 3.2 systems (IMS software version 3.2.1, Ultra-Fast Scanner [UFS] serial No. FMT0145 with software version 1.8, and Philips display PP27 QHD; Royal Philips, Amsterdam, Netherlands) as a part of digital workflow during our routine pathology practice.23 Visiopharm (VIS, Visiopharm Integrator System, Hoersholm, Denmark) DIA platform was used to assess the percentage of ER-positive cells on the stained slides. VIS DIA is an automated platform that does not require user supervision. First, ER IHC WSIs were streamed directly from our clinical IMS into VIS platform without downloading/uploading. Second, VIS DIA was able to automatically detect breast carcinoma nuclei using the built-in tumor detection algorithm with robust nuclei detection and segmentation. Finally, VIS DIA analyzed ER IHCs to divide all tumor nuclei into ER negative, weak positive, moderately positive, and strong positive staining based on the DAB intensity after setting the optimal color deconvolution (Fig. 1). The results were exported as an excel file. Some representative images with different ER staining are demonstrated in Fig. 2.

Statistical analyses

Concordance was measured using the overall percent agreement (OPA) between the VIS DIA reads and pathologists’ reads. OPA was calculated as a ratio of the numbers of cases which DIA’s read was in agreement with original pathologists’ read to the total number of cases. Statistical analysis was performed using SAS version 9.4 for Windows (SAS Institute, Inc, Cary, NC). An adjusted P-value of <0.05 was considered significant.

Results

Demographic characteristics of the study cohort

The study cohort was composed of 97 invasive breast carcinomas, including 73 biopsies and 24 resection specimens. There were 56 invasive ductal carcinomas, 3 invasive lobular carcinomas, 2 mixed ductal/lobular carcinomas, and 36 metastatic carcinomas (liver:12, bone:8, axillary lymph nodes:6, brain:5, supraclavicular lymph node: 3, lung:1, chest wall:1). Seventy-three (75.3%) cases were ER-positive, 40 (41.2%) cases were PR-positive, and 16 (16.5%) cases were HER2-positive (Table 1).

Fig. 1. Automated workflow of ER IHC digital imaging analysis (DIA) using Visiopharm coupled with whole slide images (WSI) in the Philips Image Management System (IMS). (A) Downloading case metadata for 1 ER IHC slide in Philips Imaging Managing System. (B) Streaming whole slide image of ER IHC slide by opening its metadata file in Visiopharm. (C) Selecting tumor detection and ER digital imaging analysis algorithms in Visiopharm app center. (D) Analyzing ER results using automated ER digital imaging analysis algorithm.
Correlation between ER IHC automated DIA scores and pathologists’ scores

The overall concordance between pathologists’ reads and VIS reads was excellent (93.8%). Out of the 73 ER-positive cases, Visiopharm (VIS) DIA categorized 70 (95.9%) as ER-positive. Twenty-one (87.5%) of the 24 ER-negative cases were also classified as ER-negative by VIS DIA platform (Table 2). Since low ER expressing breast carcinomas (1–10% ER positivity) are usually treated like triple negative breast carcinomas, we further investigated the concordance between pathologists’ reads and VIS reads using a 3-tiered system (ER <1%, ER 1–10%, ER >10%) and the results are shown in Table 3. One case had 85% on original report but 10% by VIS. The cause for this large difference was due to the cutoff threshold in VIS. After adjustment, this case was re-reported in 70%–80% range by VIS. There were 3 cases with low ER on original reports but more than 10% on VIS. All these 3 cases had DCIS intermixed with invasive carcinoma, causing false increase of positive percentage.

Pearson Correlation Coefficient of the percentage of ER positive nuclei between the original reads and VIS reads was 0.84776 (n = 97; P < .0001) [y = 1.1283x + 10.443 (R² = 0.7187)] (Fig. 3). This formula and the diagram demonstrate DIA reads were lower than pathologists’ reads across the board.

In addition, 2 pathologists evaluated ER IHC WSIs independently. The concordance between pathologist 1 and the original read was 92.8% while that between pathologist 2 and original read was 100% (Table 2). Hence, VIS-automated DIA’s performance was comparable with the manual estimation of ER by pathologists.

Cases with discordant ER results and pitfalls in automated ER IHC DIA

Discordance between pathologists’ read and VIS reads was seen in 6 cases, including 3 ER-negative and 3 ER-positive cases, respectively. The

Table 1
Demographic features of study cohort.

| Case #/average %/range | Cases (n = 97) |
|------------------------|---------------|
| Age (years)            | 57            |
| Biopsy                 | 73            |
| Resection              | 24            |
| Histologic type        | 56            |
| IDC                    | 3             |
| Mixed IDC/ILC          | 3             |
| Metastatic carcinoma   | 2             |
| Estrogen receptor      | 73            |
| Positive               | 24            |
| Progesterone receptor  | 40            |
| Negative               | 57            |
| HER2 IHC               | 52            |
| Negative (0/1 +)       | 29            |
| Equivocal (2 +)        | 16            |
| Positive (3 +)         | 16            |

Abbreviations: IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma, IHC: immunohistochemistry.

Fig. 2. Example of ER quantification by Visiopharm. The left panel of images (A, C, E) shows ER IHC staining, and the right panel (B, D, F) shows cell segmentation and ER quantification with pseudo-colors (blue: negative staining; red: positive staining). Invasive carcinoma is automatically detected and outlined by the algorithm. (A, B) ER with 1.5% positive staining; (C, D) ER with 67% positive staining; (E, F) ER with 96% positive staining. In (D) and (F), red lines outline the excluded non-tumor components within tumoral areas, such as necrosis, stroma, etc.
detailed information of these cases is summarized in Table 4. Briefly, all 3 false-negative cases had very weak ER staining and no more than 10% positivity. The causes for false-positive DIA included intermixed benign glands in tumor area (Fig. 4A-B), ductal carcinoma in-situ (DCIS) components (Fig. 4E-F), and tissue folding (Fig. 4C-D). On the other hand, faint ER staining caused false negative DIA results (Fig. 4G-H). After manually removing the false positivity causing areas, DIA was able to analyze those 3 false-positive cases to be negative. After adjustment of the threshold used to separate positive from negatively stained cells, all 3 false-negative cases were re-analyzed by DIA as positive (Table 4).

Discussion

Studies have demonstrated that DIA can produce rapid, uniform results with improved precision for biomarker assessment, such as ER. Most studies examined algorithms that require input and training by pathologists without automated digital workflow, which required separate slide scanning, WSI uploading to DIA platform, manual selection of region of interest (ROI), causing additional workload and delayed results.

This study aimed to validate automated ER IHC DIA in a real clinical digital workflow and provided critical information highlighting the importance regarding its innovation, automation, accuracy, and the time-consumed. Like other surgical pathology slides, ER IHC slides were scanned and stored in pathology IMS during our routine digital workflow. For automated DIA, ER IHC WSIs were streamed directly from IMS into VIS platform without downloading/uploading. VIS DIA automatically detected breast carcinoma nuclei on ER IHC WSIs using the built-in tumor detection algorithm, divided all tumor nuclei into ER negative and positive staining and calculated the percentage of positively stained tumor nuclei and staining intensity. The entire DIA process was performed by our image analysis specialist, who has no diagnostic pathology expertise. In addition, once all ER IHC WSIs were streamed into VIS platform, a batch DIA process with all WSIs was performed instead of processing WSI one-by-one. This batch process was fully automatic, without requiring any manual intervention. The results for all the cases were exported as an excel file at the end. The time spent on DIA for each case was recorded to be an average of 2.87 min, however, majority of the time was spent on the final imaging analysis. Breast biomarkers are routinely evaluated in batches at many institutions; therefore, this automated batch process will save time and labor.

Our data from the automated DIA in a clinical setting has demonstrated that automated ER IHC DIA is a reliable measurement for ER protein

![Fig. 3. Correlation between the percentage of ER positive nuclei evaluated by DIA and by pathologists. The Pearson correlation coefficient (r) was 0.84776 (n = 97; P < .0001). (y = 1.1283x + 10.443. R² = 0.7187) The red circled case had 85% on original report and 10% by VIS as shown on the histogram and this was not a discordant case but had a large difference for the percentage of ER positively stained tumor cells. The cause for this large difference may be due to the cutoff threshold in VIS. After adjustment, this case was reported in 70%–80% range by VIS. The green circled case in Fig. 3 represents a case with 2% of ER on the original report but 89% by VIS. This large percentage of difference was caused by the presence of DCIS which had more positively stained cells than invasive carcinoma. The other 2 cases with low ER on original reports but more than 10% on VIS also had DCIS intermixed with invasive carcinoma, causing false increase of positive percentage.](image-url)
expression, showing an excellent concordance with pathologists’ manual scoring (93.8%). Our results are consistent with previous studies which have shown high agreement between ER DIA and manual scoring in breast cancer specimens.\(^\text{17,18,20,22}\) Pearson correlation analysis between DIA and pathologists’ reads revealed a formula of \(y = 1.1283x + 10.443\) (\(R^2 = 0.7187\)), suggesting DIA generally yielded lower values than pathologists. This may be caused by overestimation from pathologists or a higher threshold for separating positive from negatively stained cells in the DIA algorithm. The latter possibility is more likely since the 3 false-negative cases were correctly assessed after adjusting the threshold.

It is potentially feasible to apply DIA on cytology specimens such as cell block sections. Previous study has demonstrated non-inferiority for interpreting breast cancer biomarkers on cell block WSIs.\(^\text{24}\) Our preliminary data suggest tumor detection algorithm in current ER DIA can reliably detect tumor cells in cell block sections. In addition, breast carcinomas in cytology specimens are mostly metastasis and in situ carcinoma component does not exist to interfere the interpretation of ER IHCs. Additionally, we have tested the ER DIA for progesterone receptor (PR) IHC quantification and obtained good concordance results. It would be interesting to see how this DIA works for other markers with nuclear stain.

---

**Table 4**

| Case # | ER DIA (positive/negative) | Initial ER DIA value (%) | ER DIA value after manual correction (%) | ER original read (positive/negative) | ER original read value (%) | Potential reasons for discordance |
|-------|---------------------------|--------------------------|------------------------------------------|-------------------------------------|----------------------------|---------------------------------|
| 1     | Positive                  | 8.9%                     | 0.73%                                    | Negative                            | 0.0                        | Scattered benign glands included in ROI |
| 2     | Positive                  | 15%                      | 0.0%                                     | Negative                            | 0.0                        | DCIS is included in ROI          |
| 3     | Positive                  | 1.6%                     | 0.6%                                     | Negative                            | 0.0                        | Tissue fold resulting in non-specific staining |
| 4     | Negative                  | 0.81%                    | 1.5%                                     | Positive                            | 5.0%                       | Weak staining                    |
| 5     | Negative                  | 0.96%                    | 2.5%                                     | Positive                            | 10.0%                      | Weak staining                    |
| 6     | Negative                  | 0.41%                    | 1.06%                                    | Positive                            | 10.0%                      | Weak staining                    |

Abbreviations: DIA: digital imaging analysis; ER: estrogen receptor; ROI: region of interest; DCIS: ductal carcinoma in situ.

---

**Fig. 4.** Representative images from cases with discordant results. (A, B) One false-positive case with intermixed benign glands. (C, D) One false-positive case due to tissue folds. (E, F) One false-positive case with staining in DCIS. (G, H) One false-negative due to weak nuclear staining. (A, C, E, G) Original ER-stained immunohistochemical images. (B, D, F, H) Immunohistochemical images with pseudo-colors (blue: negative staining; red: positive staining).
We have identified several pitfalls in the automated ER DIA process, including intermixed benign ducts, DCIS components, and tissue folding, that cause false-positive results; and very faint ER IHC staining to cause false-negative results. These pitfalls are not infrequent (6/97, 6%), but most of them can be avoided by simple manual annotation of region-of-interest (i.e., excluding intermixed benign ducts, DCIS components, and tissue folding) or by adjustment of the threshold used to separate positive from negatively stained cells.

To summarize, we demonstrate that automated ER IHC DIA is a valid tool to determine ER status in breast carcinoma with a high concordance to pathologists’ scoring. Furthermore, we show that integrating automated biomarker DIA into a busy clinical digital workflow is feasible and may save time and labor for pathologists.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

1. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol Off J United States Can Acad Pathol 1996;11(2):155–168.
2. Hahnel R, Woodings T, Vivian AB. Prognostic value of estrogen receptors in primary breast cancer. Cancer 1997;94(2):671–675.
3. Fitzgibbons PI, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124(7): 966–978.
4. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 2011;28(14):2784–2795.
5. Nadji M, Gomez-Fernandez C, Ganji-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005;123(1):21–27.
6. Manns GB, Fahey VD, Feleppa F, Buchanan MR. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 2005;23(22):5148–5154.
7. Hede K. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst 2008;100(12):836–837.844.
8. Collini LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol 2005;123(1):16–20.
9. Badve SS, Baehner FL, Gray RP, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008;26(15):2473–2481.
10. Giocca DR, Elledge R. Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 2000;13(1):1–10.
11. Gelber RD, Gelber S. Facilitating consensus by examining patterns of treatment effects. The Breast 2009;18:52–58.
12. Reisenschieler BS, Lenter SC, Richardson AL, Dillon DA, Ly A, Brock JE. Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting ER in breast carcinomas: a demonstration of the difficulties of consistently reporting low levels of ER expression by manual quantification. Am J Clin Pathol 2013;140(4):487–494.
13. Vasile G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol 2007;25(25):3846–3852.
14. Bera K, Schapfer KA, Rimm DL, Velcheli V, Madabhushi A. Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology. Nat Rev Clin Oncol 2019;16(11):703–715.
15. Thomsen C, Nielsen S, Nielsen BS, Pedersen SH, Vyberg M. Estrogen receptor-alpha quantification in breast cancer: concordance between immunohistochemical assays and mRNA in situ hybridization for ESR1 gene. Appl Immunohistochem Mol Morphol 2019;28(5):347–353.
16. Bolton KL, Garcia-Closas M, Peiffer RM, et al. Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res cosponsored by the American Society of Preventive Oncology 2010;19(4):999–1009.
17. Diaz LK, Sahin A, Sneege N. Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods. Am J Surg Pathol 2004;28(1):23–27.
18. Faratian D, Kay C, Robson T, et al. Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM trial experience. Histopathology 2009;55(5):587–593.
19. Rizzardi AE, Johnson AT, Vogel RJ, et al. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 2012;7:42.
20. Turbin DA, Leung S, Cheang MC, et al. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat 2008;110(3):417–426.
21. Gokhale S, Rosen D, Sneege N, et al. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol 2007;15(4):451–455.
22. Reddipea E, Brennan DJ, Holloway P, et al. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res BCR 2008;10(5):889.
23. Lujan GM, Savage J, Shana’a A, et al. Digital pathology initiatives and experience of a large academic institution during the coronavirus disease 2019 (COVID-19) pandemic. Arch Pathol Lab Med 2021;145(9):1051–1061.
24. Salama AM, Hanna MG, Giri D, et al. Digital validation of breast biomarkers (ER, PR, AR, and HER2) in cytology specimens using three different scanners. Mod Pathol Off J United States Can Acad Pathol 2022;35(1):52–59.